Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 5.1% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NTLA) is a biotechnology company focused on developing CRISPR/Cas9-based therapies for genetic diseases. The company has been actively involved in clinical trials for various conditions.

Why is Intellia Therapeutics, Inc. going down?

NTLA stock is down 5.1% on Mar 5, 2026 20:41

• The bearish movement in NTLA stock today could be attributed to profit-taking by investors after a recent surge in the stock price.
• Actions impacting GLP-1 compounders by the FDA might have raised concerns about regulatory scrutiny in the biotech sector, negatively affecting NTLA's stock.
• Despite positive clinical news and increased stake by Vanguard Group Inc., the overall market sentiment towards biotech companies like Intellia might have been affected by the uncertainty surrounding FDA actions and regulatory compliance.
• Insider sales at Intellia, the company's pre-revenue status, and negative margins could have also contributed to the bearish sentiment among investors.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

FDA again targets GLP-1 compounders; Intellia to restart heart disease trial

The FDA has issued 30 warning letters to telehealth companies for making false claims about compounded GLP-1 products, marking its second round of such actions. Separately, Intellia Therapeutics received clearance to resume a Phase 3 trial for a heart condition, having implemented new safeguards after a participant's death. Furthermore, United Therapeutics' pulmonary arterial hypertension drug, ralinepag, surpassed expectations in a Phase 3 trial, and Merck detailed positive study results for its kidney cancer drug, Welireg.

https://www.biopharmadive.com/news/fda-compounders-intellia-acip-ralinepag-merck-walireg/813555/

Intellia Therapeutics Presents Longer-Term Clinical Data

Intellia Therapeutics presented longer-term clinical data for its investigational drug lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE) at the AAAAI 2026 meeting. The presentations highlighted three-year follow-up data showing deep, stable, and durable reductions in plasma kallikrein and HAE attacks with a one-time 50 mg dose of lonvo-z. The company also presented survey findings underscoring the ongoing burden and unmet needs for HAE patients, positioning lonvo-z as a potential first one-time treatment for the condition.

https://www.globenewswire.com/news-release/2026/03/03/3248214/0/en/intellia-therapeutics-presents-longer-term-clinical-data-for-lonvoguran-ziclumeran-lonvo-z-hereditary-angioedema-hae-patient-focused-research-at-aaaai-2026.html

Intellia Therapeutics (NTLA) CMO awarded options and RSUs in Form 4 filing

Intellia Therapeutics' Executive Vice President and Chief Medical Officer, David Lebwohl, reported equity awards in a recent Form 4 filing. He received 14,204 stock options and 9,943 restricted stock units (RSUs) on March 1, 2026, increasing his direct ownership in the company to 131,192 shares of Common Stock. The stock options have an exercise price of $0.00 and RSU shares were also acquired at $0.00, with specific vesting schedules detailed for the options.

https://www.stocktitan.net/sec-filings/NTLA/form-4-intellia-therapeutics-inc-insider-trading-activity-93fee4553a9a.html

Vanguard Group Inc. Acquires 192,651 Shares of Intellia Therapeutics, Inc. $NTLA

Vanguard Group Inc. increased its stake in Intellia Therapeutics, Inc. by 1.8% in the third quarter, acquiring an additional 192,651 shares. This brings Vanguard's total holdings to 11,044,820 shares, representing approximately 10.29% of Intellia Therapeutics, valued at $190.7 million. The article also notes recent positive clinical news for Intellia and highlights varied analyst ratings, with an average "Hold" and a consensus price target of $18.50.

https://www.marketbeat.com/instant-alerts/filing-vanguard-group-inc-acquires-192651-shares-of-intellia-therapeutics-inc-ntla-2026-03-03/

Intellia Therapeutics, Inc. $NTLA is Contrarius Group Holdings Ltd's 6th Largest Position

Contrarius Group Holdings Ltd significantly increased its stake in Intellia Therapeutics (NTLA) by 279.4% in Q3 2025, making it the fund's sixth-largest holding. This comes as the FDA lifted a clinical hold on Intellia's MAGNITUDE Phase 3 IND for nexiguran ziclumeran, and the company completed enrollment for another Phase 3 trial. Despite regulatory progress and analyst upgrades, Intellia remains a pre-revenue company with negative margins, and recent insider sales have occurred.

https://www.marketbeat.com/instant-alerts/filing-intellia-therapeutics-inc-ntla-is-contrarius-group-holdings-ltds-6th-largest-position-2026-03-03/

Trending Today

Tapestry Inc. ($TPR) Stock Forecast: Up 6.1% Today

United Continental Holdings Inc. ($UAL) Stock Forecast: Up 6.3% Today

Cboe Global Markets Inc. ($CBOE) Stock Forecast: Down 6.1% Today

Estee Lauder Companies Inc. (The) ($EL) Stock Forecast: Up 6.1% Today

Carnival Corporation ($CCL) Stock Forecast: Up 6.8% Today

Workday Inc. ($WDAY) Stock Forecast: Down 6.0% Today

Delta Air Lines Inc. ($DAL) Stock Forecast: Up 5.5% Today

Teradyne, Inc. ($TER) Stock Forecast: Up 6.3% Today

Keysight Technologies Inc. ($KEYS) Stock Forecast: Up 5.2% Today

Franco-Nevada Corp. ($FNV) Stock Forecast: Up 6.0% Today

Intellia Therapeutics, Inc. Price History

26.01.2026 - NTLA Stock was up 10.7%

• After revealing its Q4 earnings, NTLA stock saw a noteworthy increase in value, surprising analysts who had forecast a marginal decrease in both EPS and revenue compared to the previous year.
• The FDA's decision to remove a clinical hold on Intellia's gene-editing medication had a favorable impact on the stock's performance, hinting at potential competitiveness in the rare disease pharmaceuticals market.
• Intellia's upcoming involvement in investor conferences scheduled for March 2026 also played a role in boosting market confidence, as investors displayed keen interest in the company's strategic vision and growth prospects.

05.01.2026 - NTLA Stock was down 6.0%

• The decline in NTLA's stock value today might be due to investors selling to realize profits following a previous uptick in price.
• Despite receiving approval for its clinical trial and a raised price target, concerns about the company's long-term profitability may have shifted market sentiment.
• The market may be reacting to the company's ongoing losses despite positive regulatory news, causing uncertainty about its future financial performance.
• Investors might be wary of the continued clinical hold on the MAGNITUDE trial for ATTR-CM, which could be viewed as a risk factor affecting the stock's movement.

13.01.2026 - NTLA Stock was up 8.7%

• The FDA's decision to lift the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran was a significant positive driver for the stock, leading to a notable increase in share price.
• Despite this positive development, concerns about the company's profitability and high price-to-sales ratio relative to industry averages have sparked discussions about the stock's valuation and future growth prospects.
• Analysts, on average, recommend holding the stock with a price target of $18.00. Insider selling and institutional ownership changes contribute to the mixed outlook on NTLA's valuation and potential future performance.

05.02.2026 - NTLA Stock was down 5.1%

• The bearish movement in NTLA stock today could be attributed to profit-taking by investors after a recent surge in the stock price.
• Actions impacting GLP-1 compounders by the FDA might have raised concerns about regulatory scrutiny in the biotech sector, negatively affecting NTLA's stock.
• Despite positive clinical news and increased stake by Vanguard Group Inc., the overall market sentiment towards biotech companies like Intellia might have been affected by the uncertainty surrounding FDA actions and regulatory compliance.
• Insider sales at Intellia, the company's pre-revenue status, and negative margins could have also contributed to the bearish sentiment among investors.

05.02.2026 - NTLA Stock was down 5.1%

• Despite recent positive developments, such as analyst upgrades, strong financial results, and progress with its Phase 3 trial after regulatory hurdles were resolved, Intellia Therapeutics saw a decline in its stock price.
• The market response may have been influenced by the company's decision to expand its At-The-Market offering program to $1.04 billion, which could potentially lead to dilution of existing shares and impact shareholder value.
• Concerns regarding the company's financial performance, such as negative margins and a high valuation, despite advancements in its pipeline and clinical work, might have unsettled investors.
• The divergence in opinions among analysts and the uncertainty surrounding Intellia's path to profitability likely contributed to the negative market sentiment, even amidst positive strides in its therapeutic initiatives.

03.02.2026 - NTLA Stock was down 5.1%

• The stock price of Intellia Therapeutics plummeted despite recent positive developments and analyst upgrades, indicating a possible case of "buy the rumor, sell the news" behavior among investors.
• The FDA's decision to lift the clinical hold on the MAGNITUDE Phase 3 trial for a key therapy was initially seen as a positive development, but concerns over the safety and efficacy of the treatment may have led to the market's negative reaction.
• The company's decision to increase its At-The-Market offering program to $1.04 billion could have also contributed to the bearish sentiment, signaling potential dilution of existing shares and impacting shareholder value.
• Overall, the market movement suggests that investors may be exercising caution and reevaluating their positions in Intellia Therapeutics amidst a mix of positive news and financial decisions by the company.

24.01.2026 - NTLA Stock was up 5.7%

• The development of an investigational gene editing therapy for hereditary transthyretin (ATTR) amyloidosis through CRISPR/Cas9 technology has likely spurred investor optimism and interest in Intellia Therapeutics.
• Encouraging reduction in harmful protein production observed in early clinical trial findings could pave the way for advancements in treating genetic disorders, potentially enhancing the company's standing and stock performance.
• Noteworthy institutional investments, such as those from Jupiter Asset Management Ltd. amounting to $23.52 million, signal increasing confidence in Intellia Therapeutics' future prospects and may have influenced the recent positive market trend.
• Anticipation surrounding an imminent conference call to discuss financial results and business updates could be fueling positive investor sentiment and driving up the stock price.

19.01.2026 - NTLA Stock was up 6.3%

• The bullish movement in NTLA stock today is linked to the lifting of the clinical hold on the MAGNITUDE-2 study, enabling expanded enrollment and updated safety protocols.
• The scheduled conference call to discuss fourth-quarter and full-year 2025 financial results and business updates likely impacted investor confidence in the company's future.
• H.C. Wainwright's increased price target and reiterated Buy rating contributed to a positive investor sentiment towards Intellia Therapeutics.
• Investor optimism about Intellia's gene-editing platform has been bolstered by regulatory clearance and the company's safety improvement efforts, driving the bullish market movement.

10.01.2026 - NTLA Stock was down 5.2%

• Despite recent developments in its MAGNITUDE-2 Phase 3 trial, Intellia Therapeutics (NTLA) saw a 6.6% decline in its stock price.
• Concerns over the ongoing hold on another trial, ATTR-CM MAGNITUDE, have affected investor confidence and contributed to the stock's bearish movement.
• Analysts' decision to maintain a "Hold" rating, reduce price targets, and insider selling have further impacted the sentiment surrounding NTLA's stock.
• The company's status as currently loss-making, alongside debates on its valuation, has led to increased stock volatility and caution among investors regarding future regulatory challenges.

18.01.2026 - NTLA Stock was up 5.1%

• The surge in NTLA stock can be linked to the regulatory approval to resume the MAGNITUDE-2 study with expanded enrollment and enhanced safety protocols.
• Analysts, including H.C. Wainwright, have raised price targets and reiterated Buy ratings on NTLA, showing increased confidence in the company's gene-editing technology.
• Investors are focusing on the trial progress, safety updates, and Intellia's path to profitability amid industry competition despite regulatory advancements.
• The decision to lift the clinical hold marks a significant milestone for Intellia, potentially altering its risk profile and impacting future pricing discussions and partnership opportunities.

27.01.2026 - NTLA Stock was up 5.2%

• Intellia Therapeutics (NTLA) reported a Q4 loss of $0.83 per share, but exceeded revenue estimates, indicating strong potential for revenue growth.
• The positive momentum was driven by an earnings beat, promising trial data for hereditary angioedema, and the release of an FDA clinical hold, boosting investor confidence in the company's pipeline.
• The stock's valuation narrative is mixed, with discussions about high current multiples but substantial undervaluation based on future revenue potential, emphasizing the significance of upcoming milestones such as the Phase 3 HAELO trial for future growth.
• Despite recent share price increases, the company's three-year return is negative, signaling investor optimism about Intellia Therapeutics' long-term prospects despite some short-term obstacles.

02.02.2026 - NTLA Stock was up 5.6%

• Intellia Therapeutics observed a significant uptrend in trading today, driven by a variety of positive developments:
• The company posted strong Q4 2025 earnings and revenue, surpassing expectations and demonstrating robust financial performance.
• Analysts at Chardan Capital reiterated a "Buy" rating with a target price of $26, showcasing confidence in the company's growth trajectory.
• Investor optimism has been fueled by Intellia's focus on its lonvo-z candidate for HAE, with upcoming Phase 3 data and a BLA submission.
• The FDA's removal of the clinical hold on Intellia's MAGNITUDE-2 trial for its gene-editing programs has further bolstered positive sentiment surrounding the stock.